Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03149029
Title Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Massachusetts General Hospital



Dabrafenib + Pembrolizumab + Trametinib

Pembrolizumab + Trametinib

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Beth Israel Deaconess Medical Center Boston Massachusetts 02115 United States Details
Massachusetts general Hospital Boston Massachusetts 02115 United States Details
*Shaded cells indicate that there was no data available from for the field